A study to evaluate the efficacy and the safety of single pill combination (SPC) ezetimibe/rosuvastatin in Chinese adult patients with primary hypercholesterolemia not adequately controlled on statin therapy

Trial Identifier: LPS16135
Sponsor: sanofi
Start Date: December 2020
Primary Completion Date: June 2022
Study Completion Date: June 2022
Condition: Hypercholesterolemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Baotou, China, 014010
China Beijing, China, 100050
China Beijing, China, 100029
China Beijing, China, 101200
China Bengbu, China
China Changchun, China, 130033
China Changchun, China, 130021
China Changsha, China, 410013
China Chengdu, China, 610041
China Chongqing, China, 400013
China dalian, China, 116033
China Haikou, China, 570311
China hohhot, China, 010050
China Hohhot, China, 010017
China Jilin, China, 132011
China Jinan, China, 250013
China Lishui, China, 323000
China Liuzhou, China, 545006
China Nanjing, China, 210011
China Nanning, China, 530031
China Shanghai, China, 200120
China Shenyang, China, 110016
China Siping, China, 136000
China Tianjin, China, 300140
China Tianjin, China, 300121
China Wuhan, China, 430080
China Wuhan, China, 430033
China Wuhan, China, 430022
China Xi'an, China, 710068
China Xi'An, China, 710061
China Xuzhou, China, 221002
China yangzhou, China, 225001
China Yanji, China, 133000
China Yinchuan, China, 750004
China Yueyang, China, 414000
China yuncheng, China, 044000
China Zhanjiang, China, 524001
China Zhenjiang, China, 212001
China Zhuzhou, China, 412007
China Zibo, China, 255036